Type 1 Diabetes Mellitus Clinical Trial
Official title:
Influence of Sucrose-free Diet or Sucrose-added Diet on Glucose Variability in Patients With Type 1 Diabetes
BACKGROUND: The treatment with continuous glucose monitoring system (CGMS) offers improved
glycemic control for patients with type 1 diabetes. However, patients with type 1 diabetes
usually intake foods with sugar, even without hypoglycemic episodes, and the use of advanced
carbohydrate counting method may increase the calories and carbohydrate intake.
OBJECTIVE: To evaluate and compare the influence of sucrose-free diet or sucrose-added diet
on glucose variability in patients with type 1 diabetes.
METHODS: The study was a simple-blind, two-way crossover design in which patients with type 1
diabetes will receive a control diet (a diet with a little quantity of sugars) or test diet
(with foods containing moderate quantity of sucrose in composition) during two-days each.
During the intervention, all foods and drinks intake will have to be documented to allow
quantitative estimation of dietary intake, to verify adherence to the diets. After one-week,
each patient will return for download CGMS.
PURPOSE: The research proposal adds knowledge about the glucose variability in patients with
type 1 diabetes who use foods with sugar in theirs habitual dietary intake.
INTRODUCTION:
The continuous glucose monitoring system (CGMS) offers improved glycemic control for patients
with type 1 diabetes, because may reduce asymptomatic hypoglycemic and postprandial
hyperglycemia events (1, 2).
Glycemic disorder may be estimated as a whole from the determination of glycosylated
hemoglobin (HbA1c) level, which integrates both hypoglycemic and hyperglycemia episodes (3).
Glycemic variability is a complex phenomenon that includes both intraday and interday
variability (3, 4).
The mean amplitude of glycemic excursion (MAGE) is an index for assessing the intraday
glycemic variability. The calculation of the MAGE is obtained by measuring the arithmetic
mean of the differences between consecutive peaks and nadirs provided that the differences
are greater than one standard deviation (SD) of the mean glucose value (5).
The continuous overall net glycemic action (CONGA) index is an indicator of within-day
glucose variability. After the first n number of hours of observation, the investigators may
calculate the difference between current observation and observation in the previous n hours.
CONGA is defined as the SD of the recorded differences. The frequently used index CONGA1,
CONGA2 and CONGA4, coincide with observations lasting 1, 2, or 4 h and they are, therefore,
expressions of glucose variability within these intervals (6).
The mean of daily differences (MODD) remains the sole index for estimating interday glycemic
variability. This index is calculated as the mean of the absolute differences between glucose
values at the same time on two consecutive days (3, 7).
Some of these indexes are complex or impossible to obtain with self-monitoring of blood
glucose (SMBG). Thus, the CGMS allows to the calculation of scores (7).
Another aspect of diabetes treatment is the nutritional counseling. According to individuals
with type 1 diabetes, diet adherence is one of the more difficult aspects of treatment (8,
9). However, nutrition therapy is essential in the management of diabetes, and meal-planning
strategies for type 1 diabetes emphasize the relationship between prandial insulin dose
selection and the anticipated amount of carbohydrates to be consumed (10, 11).
Carbohydrate counting is a meal-planning method that focuses on carbohydrates, and the
American Diabetes Association recommends meal plans based on carbohydrate counting as a key
strategy to achieving glycemic control (11).
There are two levels of carbohydrate counting. At the basic level, individuals must eat a
consistent amount of carbohydrates at meals. It is useful to understand the effect of food
and medication and to identify normal portion sizes, considering that one serving is equal to
15g of carbohydrates. The advanced level includes pattern management and understanding how to
use insulin-to-carbohydrate ratios. Carbohydrate counting requires the ability to determine
the amount of carbohydrates in each food, and it may promote weight gain when patients don't
pay attention to their food choices (10, 12).
Our previous study has shown that patients with type 1 diabetes who began carbohydrate
counting, especially the advanced method, increased their calories and carbohydrates intake
(13).
Sucrose is a very attractive source of carbohydrate, and sweetness is considered one of the
most powerful determinants of food consumption (14). Patients with diabetes type 1 appear to
be especially prone to taste disorders (8).
Our previous study has shown that patients with type 1 diabetes's habitual intake sweets more
than twice a week, despite hypoglycemia (13).
The use of CSII associated with the advanced carbohydrate counting may increase the calories
and carbohydrate intake (15-18).
Previous studies have showed that the use of CSII with CGMS improve glycemic control,
However, no study has evaluated the glucose variability in patients with type 1 diabetes in a
diet with foods containing moderate quantity of sucrose.
The goal of this study is to evaluate and compare the influence of sucrose-free diet or
sucrose-added diet on glucose variability in patients with type 1 diabetes, treated with CSII
and CGMS.
EXPERIMENTAL DESIGN:
STUDY DESIGN:
This is a single-blind, two-way, crossover design in with patients with type 1 diabetes will
be recruiting through poster advertisements or invited during routine medical appointment at
the Clementino Fraga Filho University Hospital, Brazil by an investigator.
The sample size and selection by convenience. All participants will signed an informed
consent.
Selected volunteers will be instruct to go to the hospital for anthropometric measurements,
and insert the glucose sensor iPro2™ Professional CGMS system (Medtronic, Inc™). In addition,
all volunteers will be receiving instructions to fill a 7-day food diary, and register their
self-capillary blood glucose (four times/day).
In the same day, volunteers will receive a control diet (a diet with a little quantity of
sugars) or test diet (with foods containing moderate quantity of sucrose in composition)
during two-days each. These diets are composed by two menus: control diet for Tuesday and
Wednesday, and test diet for Thursday and Friday.
If the volunteers consume the menus correctly during Tuesday to Friday, the diet on weekends
is free. However, if a meal was consumed improperly (eg. more or less amounts, or inadequate
replacements), Saturday or Sunday should be used to follow the menu not completed properly.
The researcher will contact daily in order to clarify possible doubts, and verify adherence
to the diets.
After one-week, each volunteer will return for download CGMS, and in order to deliver the
7-day food diary.
INTERVENTION:
Percent energy from macronutrients was similar in both diets, and these were prescribed
according to the American Diabetes Association guidelines (11).
Dietary energy content of: 50.7% and 54.6% carbohydrates; 21.5% and 21.2% protein; 27.7% and
23.42% total fat; 5.0% and 4.9% saturated fatty acids; 15.1% and 12.8% monounsaturated fatty
acids; 7.3 and 5.9% polyunsaturated fatty acids; for control and test diets, respectively.
Both diets were composed by 41g total dietary fiber.
Control diet has little quantity of sugars (30.4g/day, corresponding to 12.7% of total
carbohydrates and 6.3% of total dietary energy intake), and test diet has foods containing
moderate quantity of sucrose in composition (81.2g/day, corresponding to 30.2% of total
carbohydrates and 16.5% of total dietary energy intake).
These diets are composed by two menus: control diet for Tuesday and Wednesday, and test diet
for Thursday and Friday. The diet on weekends is free, if the volunteers consume the menus
correctly during Tuesday to Friday. However, if a meal was consumed improperly (eg. more or
less amounts, or inadequate replacements), Saturday or Sunday should be used to follow the
menu not completed properly.
DIETARY ASSESSMENT:
Dietary intake will be evaluated from. All dietary records will be analyzed using a local
nutritional software.
During those seven days, all foods and drinks consumed will have to be documented to allow
quantitative estimation of dietary intake. Data were then entered into the DietPró 5.5i
nutrition software (version 2010, Brazil) to convert the amount of food eaten into individual
nutrients and the mean daily energy and nutrient intake for each patient will be calculated.
ANTHROPOMETRIC ASSESSMENT:
Body mass index (BMI) will be calculated as body weight in kilograms divided by the square of
height in meters.
Waist circumference will be determined as the average of two measurements calculated to the
nearest 0.1cm midway between the lower rib margin and the ilial crest after a normal
expiration.
STATISTICAL:
Statistical analyses will be performed in SPSS software (version 20.0; SPSS Inc, Chicago, IL,
USA). A p-value <0.05 will be consider statistically significant.
Qualitative variables were described as frequency, whereas quantitative variables will be
describe as the mean ± standard deviations (SD) and 95% CI.
The Mann-Whitney test will be used for between-group comparison and the Wilcoxon test will be
used to compare the effects of tests in each group. Spearman correlation and linear
regression will be used to evaluate interactions.
Time course of glycemic datas will be analyzed with repeated measures analysis of variance
two-way ANOVA.
The glycemic variability (MAGE, CONGA and MODD) will be calculated according to described by
Kovatchev et al (3, 7).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04476472 -
Omnipod Horizon™ Automated Glucose Control System Preschool Cohort
|
N/A | |
Completed |
NCT03635437 -
Evaluation of Safety and Diabetes Status Upon Oral Treatment With GABA in Patients With Longstanding Type-1 Diabetes
|
Phase 1/Phase 2 | |
Completed |
NCT04909580 -
Decision Coaching for Youth and Parents Considering Insulin Delivery Methods for Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT00679042 -
Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol
|
Phase 3 | |
Completed |
NCT03293082 -
Preschool CGM Use and Glucose Variability in Type 1 Diabetes
|
N/A | |
Completed |
NCT04016662 -
Automated Insulin Delivery in Elderly With Type 1 Diabetes (AIDE T1D)
|
Phase 4 | |
Completed |
NCT02527265 -
Afrezza Safety and Pharmacokinetics Study in Pediatric Patients
|
Phase 2 | |
Completed |
NCT03738865 -
G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes
|
Phase 3 | |
Completed |
NCT03240432 -
Wireless Innovation for Seniors With Diabetes Mellitus
|
N/A | |
Completed |
NCT03168867 -
Effectiveness Trial of an E-Health Intervention To Support Diabetes Care in Minority Youth (3Ms)
|
N/A | |
Completed |
NCT03674281 -
The VRIF Trial: Hypoglycemia Reduction With Automated-Insulin Delivery System
|
N/A | |
Completed |
NCT03669770 -
Ultrasound Classification and Grading of Lipohypertrophy and Its Impact on Glucose Variability in Type 1 Diabetes
|
||
Recruiting |
NCT03682640 -
Azithromycin Insulin Diet Intervention Trial in Type 1 Diabetes
|
Phase 2 | |
Recruiting |
NCT04096794 -
Chinese Alliance for Type 1 Diabetes Multi-center Collaborative Research
|
||
Completed |
NCT02882737 -
The Impact of Subcutaneous Glucagon Before, During and After Exercise a Study in Patients With Type 1 Diabetes Mellitus
|
N/A | |
Recruiting |
NCT02745808 -
Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Completed |
NCT02596204 -
Diabetes Care Transformation: Diabetes Data Registry and Intensive Remote Monitoring
|
N/A | |
Completed |
NCT02558491 -
Feasibility of a Decision Support System to Reduce Glucose Variability in Subject With T1DM
|
N/A | |
Withdrawn |
NCT02579148 -
Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Completed |
NCT02562313 -
A Trial Investigating the Continuous Subcutaneous Insulin Infusion of a Liquid Formulation of BioChaperone Insulin Lispro in Comparison to Humalog®
|
Phase 1 |